MedPath

Combination Treatment for Advanced Liver Cancer

Phase 3
Withdrawn
Conditions
Hepatocellular Carcinoma
Hepatic Portal Vein Tumor Invasion
Interventions
Procedure: chemoembolization
Device: endovascular stents implantation
Procedure: iodine-125 seed strand implantation
Registration Number
NCT02149771
Lead Sponsor
Shanghai Zhongshan Hospital
Brief Summary

The purpose of this study is to determine whether TACE combined endovascular stent implantation confers a survival benefit over TACE alone.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • (1) Hepatocellular carcinoma(HCC) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the American Association for the Study of Liver Diseases (AASLD) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on CT or MRI;
  • (2) Child-Pugh classification grade A or B;
  • (3)Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.
Exclusion Criteria
  • advanced liver disease (bilirubin levels >3 mg/dL, ASTor ALT >5 × upper limit of normal);
  • Tumor invade the Inferior Vena Cava, extrahepatic spread;
  • contraindications for doxorubicin or oxaliplatin chemotherapy;
  • any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/L or prothrombin activity below 50 %);
  • renal failure,cardiac ejection fraction <50 %) or end-stage disease;
  • patients who were not capable of cooperation during the procedure.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TACEchemoembolizationTransartery chemoembolisation(TACE) by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
TACE&Stentschemoembolizationchemoembolization combined with endovascular stents and iodine-125 seed strand implantation
TACE&Stentsiodine-125 seed strand implantationchemoembolization combined with endovascular stents and iodine-125 seed strand implantation
TACE&Stentsendovascular stents implantationchemoembolization combined with endovascular stents and iodine-125 seed strand implantation
Primary Outcome Measures
NameTimeMethod
Median survival time2 years
Secondary Outcome Measures
NameTimeMethod
Time to Disease Progression2 years

Trial Locations

Locations (1)

Department of Interventional Radiology, Zhongshan Hospital, Fudan University

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath